STAT+: The biotech 2021 preview, from M&A to gene therapy and more
Hello, Biotech 2021.
In the interest of humility, we’ll note that last year’s preview story made no mention at all of the coronavirus. Sadly, we paid no mind to our colleague Helen Branswell’s prescient tweet.
Continue to STAT+ to read the full story…
Read Original Article: STAT+: The biotech 2021 preview, from M&A to gene therapy and more »
